Target: ₹474
CMP: ₹227
Camlin Fine Sciences Limited (CFSL) is poised for significant growth, with expectations of a rebound in vanillin volumes in the second half of the fiscal year 2026, as tariff uncertainties diminish and festive demand in Western markets increases. Global demand for vanillin stands at approximately 33,000 tonnes per annum (ktpa), while the current capacity hovers around 41 ktpa, with methyl vanillin comprising the majority at 25–26 ktpa.
The production capacity, however, is heavily concentrated in China. Recent anti-dumping duties imposed in Europe, along with minimal U.S. imports from China, have resulted in a demand-supply imbalance.
This shift presents opportunities for Indian suppliers, and CFSL is anticipated to sell around 2,700 tonnes of vanillin in fiscal year 2026. In addition to vanillin, the company’s blends business is expanding at a high-teens growth rate, supported by its diversified presence across food and beverage antioxidants, biofuels, animal nutrition, pet food, and nutrition and health sectors.
The global market for antioxidants and blends is valued at over $18–20 billion and poses high entry barriers due to regulatory, technical, and supply chain challenges. CFSL’s advantages include backward integration, strong client relationships, and technical expertise, which enable the company to achieve superior returns on capital employed (RoCE), projected at 55% in fiscal year 2027.
The company is currently valued at 15 times one-year forward EV/EBITDA, leading to an updated target price of ₹474, up from the prior estimate of ₹425. Nevertheless, potential downside risks include a decline in vanillin prices.
Published on September 22, 2025
